SAP Announces Strategic Alliances to Drive Forward Genomic Research
News May 30, 2014
SAP AG has announced a strategic collaboration with Stanford School of Medicine to research the contribution of genetics, environmental exposures, behavior and other factors to disease susceptibility using the power of the SAP HANA® platform.
The company also announced its participation in the Global Alliance for Genomics and Health, a council of industry leaders working toward accelerating worldwide efforts to responsibly share and analyze large amounts of genomic and clinical data.
“SAP HANA has the potential to drive breakthrough innovation in genomics research and the healthcare industry overall,” said Barbara Stortz, senior vice president, SAP HANA Platform for Healthcare and SAP HANA Native Development, SAP AG. “It is a big step for SAP to closely collaborate with the Stanford School of Medicine and join the Global Alliance for Genomics and Health to ultimately enable a better understanding of genetic underpinnings of health and disease.”
Genomic Research Collaboration With Stanford School of Medicine
SAP’s collaboration with Stanford School of Medicine aims to achieve a better understanding of global human genome variation and its implications in disease, particularly cardiovascular disease. Led by Carlos D. Bustamante, professor and director of the Stanford Center for Computational, Human and Evolutionary Genomics; Euan A. Ashley, associate professor of Medicine and Genetics; and Atul J. Butte, associate professor of Pediatrics and Genetics, the collaboration aims to advance genomics research in the clinical environment, ultimately leading to improved healthcare and personalized medicine.
Researchers have already leveraged SAP HANA to corroborate the results of a study that discovered that the genetic risk of Type II Diabetes varies between populations. The study looked at 12 genetic variants previously associated with Type II Diabetes across 49 individuals. With SAP HANA, researchers in Dr. Butte’s lab were able to simultaneously query all 125 genetic variants previously associated with Type II Diabetes across 629 individuals. Using traditional methods, this analysis on this amount of data would have taken an unreasonable amount of time.
Global Alliance for Genomics and Health
The Global Alliance for Genomics and Health is an international non-profit alliance formed to help accelerate the potential of genomic medicine to advance human health. SAP joins a diverse group consisting of leading research institutions, healthcare providers and information technology and life science companies worldwide. As a member, SAP plans to contribute important perspectives and expertise to help identify best practices and establish a common framework of standards and harmonized approaches to enable the responsible, voluntary and secure sharing of genomic and clinical data.
Next Major Event: SAPPHIRE NOW With SAPPHIRE NOW, SAP offers customers, partners and prospects even more opportunities to engage in dialogue with peers, participants and thought leaders around the globe. Being held in Orlando, Florida, June 3-5, 2014, this enhanced, real-time event connects attendees on site with global participants through broadcast studios and an online experience that incorporates the latest social media and community functionality. Whether on site or online, participants can gain insight as to how SAP is delivering on its product strategy and helping organizations around the world to run better.
Gene-edited Pigs are Resistant to Billion-dollar VirusNews
Scientists have produced pigs that can resist one of the world’s most costly animal diseases, by changing their genetic code. Tests with the virus – called Porcine Reproductive and Respiratory Syndrome, or PRRS – found the pigs do not become infected at all. The animals show no signs that the change in their DNA has had any other impact on their health or wellbeing.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE